{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T19:56:05Z","timestamp":1721246165366},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.2169\/internalmedicine.1609-23","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T22:26:59Z","timestamp":1680215219000},"page":"3361-3365","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery"],"prefix":"10.2169","volume":"62","author":[{"given":"Takumi","family":"Akiyama","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Yoneyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hoyano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein (a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 16: e77-e95, 2022.","DOI":"10.1016\/j.jacl.2022.08.007"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsimikas S. A Test in context: lipoprotein (a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69: 692-711, 2017.","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Watts GF, Chan DC, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein (a) particle kinetics. Eur Heart J 39: 2577-2585, 2018.","DOI":"10.1093\/eurheartj\/ehy122"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk. Circulation 139: 1483-1492, 2019.","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kronenberg F. Human genetics and the causal role of lipoprotein (a) for various diseases. Cardiovasc Drugs Ther 30: 87-100, 2016.","DOI":"10.1007\/s10557-016-6648-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376: 1713-1722, 2017.","DOI":"10.1056\/NEJMoa1615664"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379: 2097-2107, 2018.","DOI":"10.1056\/NEJMoa1801174"},{"key":"8","unstructured":"8. Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41: 111-188, 2020."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Oyama K, Furtado RHM, Fagundes A Jr, et al. Effect of evolocumab on complex coronary disease requiring revascularization. J Am Coll Cardiol 77: 259-267, 2021.","DOI":"10.1016\/j.jacc.2020.11.011"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol 40: 255-266, 2020.","DOI":"10.1161\/ATVBAHA.119.312951"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol 80: 348-372, 2022.","DOI":"10.1016\/j.jacc.2022.05.017"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94: 1247-1254, 1996.","DOI":"10.1161\/01.CIR.94.6.1247"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Park SH, Rha SW, Choi BG, et al. Impact of high lipoprotein (a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clin Exp Pharmacol Physiol 42: 588-595, 2015.","DOI":"10.1111\/1440-1681.12396"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1609-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:20:33Z","timestamp":1700277633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1609-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":13,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1609-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1609-23"}}